Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$35.9 million.

  • Cartesian Therapeutics' Profit After Tax fell 4845.97% to -$35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.0 million, marking a year-over-year increase of 8040.31%. This contributed to the annual value of -$77.4 million for FY2024, which is 6476.08% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported Profit After Tax of -$35.9 million as of Q3 2025, which was down 4845.97% from $15.9 million recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' Profit After Tax peaked at $28.8 million during Q1 2022, and registered a low of -$177.7 million during Q4 2023.
  • Its 5-year average for Profit After Tax is -$17.1 million, with a median of -$10.3 million in 2024.
  • Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 311472.93% in 2023, then soared by 22150.7% in 2024.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Profit After Tax stood at $12.2 million in 2021, then tumbled by 51.85% to $5.9 million in 2022, then crashed by 3114.73% to -$177.7 million in 2023, then skyrocketed by 94.23% to -$10.3 million in 2024, then tumbled by 250.16% to -$35.9 million in 2025.
  • Its Profit After Tax stands at -$35.9 million for Q3 2025, versus $15.9 million for Q2 2025 and -$17.7 million for Q1 2025.